Indacaterol/mometasone furoate (Atectura Breezhaler®) accepted for use within NHSScotland

This is recommended as maintenance treatment of asthma in adults & adolescents age ≥12 years not adequately controlled with inhaled corticosteroids & inhaled short-acting beta2-agonists; it was considered to offer an additional treatment choice of these drugs in a single inhaler.

Source:

Scottish Medicines Consortium